Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 4/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8000832 | 0.88 | NR1H2 (0.40) | USP30NR1H2NR1H3UCHL1CCNT1 | |
| SCHEMBL10254818 | 0.81 | NR1H2 (0.43) | NR1H2NR1H3UCHL1CCNT1CDK9 | |
| SCHEMBL7998582 | 0.79 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1P2RX3 | |
| SCHEMBL10255074 | 0.79 | ALDH1A1 (0.41) | USP30NR1H2NR1H3UCHL1CCNT1 | |
| SCHEMBL1131373 | 0.79 | ALDH1A1 (0.41) | USP30NR1H2NR1H3UCHL1CCNT1 | |
| SCHEMBL10260293 | 0.77 | UCHL1 (0.40) | USP30NR1H2NR1H3UCHL1CCNT1 | |
| SCHEMBL8227117 | 0.75 | USP30 (0.43) | USP30NR1H2NR1H3UCHL1P2RX3 | |
| SCHEMBL7875821 | 0.75 | USP30 (0.41) | USP30NR1H2NR1H3UCHL1P2RX3 | |
| SCHEMBL31336371 | 0.75 | P2RX3 (0.46) | USP30NR1H2NR1H3UCHL1PTPN1 | |
| SCHEMBL26940536 | 0.75 | P2RX3 (0.46) | USP30NR1H2NR1H3UCHL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8273709-B2 | Triazole-containing macrocyclic HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273709-B2 | Triazole-containing macrocyclic HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009079353-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | TMPRSS4, SPINT2, PRSS1 | USP30 943/4885NR1H2 1136/4885NR1H3 758/4885 |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | USP30 1561/4885NR1H2 620/4885NR1H3 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.